株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

感染症迅速診断検査の世界市場 - 分析と予測:2020年~2025年

Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2025

発行 BIS Research Inc. 商品コード 941002
出版日 ページ情報 英文 217 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.31円で換算しております。
感染症迅速診断検査の世界市場 - 分析と予測:2020年~2025年 Global Infectious Disease Rapid Diagnostic Testing Market: Focus on Product, Disease, Technology, Application, End User, Region/Country Data, and Competitive Landscape - Analysis and Forecast, 2020-2025
出版日: 2020年06月06日 ページ情報: 英文 217 Pages
概要

世界の感染症迅速診断検査市場は、2025年までに28億5320万米ドルに達すると予測されています。

当レポートでは、世界の感染症迅速診断検査市場について調査分析し、市場概要、市場分析と予測、主要企業などについて、体系的な情報を提供しています。

目次

第1章 製品の定義

第2章 市場の範囲

第3章 調査手法

第4章 市場概要

  • 定義
  • 感染症迅速診断技術
  • 状況分析:COVID-19以前 vs. COVID-10以後
  • 感染症迅速診断検査に対するCOVID-19の影響
  • 市場規模と成長可能性 (金額)

第5章 市場力学

  • 概要
  • 影響分析
  • 促進要因
  • 抑制要因
  • 市場機会

第6章 世界の感染症迅速検査市場:製品別

  • 概要
  • アッセイ
  • プラットフォーム

第7章 世界の感染症迅速検査市場:技術別

  • 概要
  • リアルタイムPCR(q-PCR)
  • 等温核酸増幅技術(INAAT)
  • ラテラルフローイムノアッセイ(LFIA)
  • 酵素免疫測定法(EIA)
  • その他

第8章 世界の感染症迅速検査市場:適応別

  • 概要
  • 呼吸器感染症
  • 胃腸感染症
  • 中枢神経系感染症
  • 院内感染
  • 性感染症
  • その他

第9章 世界の感染症迅速検査市場:疾患別

  • 概要
  • 細菌感染
  • ウイルス感染
  • その他の感染

第10章 世界の感染症迅速診断検査市場における新興企業

  • XCR Diagnostics, Inc.
  • Co-Diagnostics Inc.
  • Inflammatix, Inc.
  • DNA Electronics
  • Mylab Discovery Solutions Pvt. Ltd.
  • CerTest BIOTEC S.L.

第11章 世界の感染症迅速診断検査市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東
  • アフリカ
  • その他の地域

第12章 世界の感染症迅速診断検査市場:エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • 診断センター
  • その他

第13章 競合情勢

  • 主な戦略と開発
  • 業界動向
  • 市場シェア分析(企業別)
  • 成長シェア分析(機会マッピング)

第14章 企業プロファイル

  • 概要
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Danaher Corporation
  • Luminex Corporation
  • BGI Group
  • bioMerieux S.A.
  • DiaSorin S.p.A
  • Hologic, Inc.
  • Mesa Biotech
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • GenMark Diagnostics
  • CTK Biotech
  • Becton, Dickinson and Company
  • Cellex
図表

List of Tables

  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact Analysis of Market Restraints
  • Table 6.1: Key Rapid Diagnostic Assays Offered for Infectious Disease
  • Table 6.2: Key Platforms Offered for Infectious Disease
  • Table 7.1: Key Products Offered Based on RT-PCR
  • Table 7.2: Key Products Offered Based on INAAT
  • Table 7.3: Key Products Offered Based on LFIA
  • Table 7.4: Key Products Offered Based on EIA
  • Table 7.5: Key Products Offered Based on Other Technologies
  • Table 8.1: Key Products Offered for COVID-19 Diagnosis
  • Table 8.2: Key Products Offered for Respiratory Infection Diagnosis
  • Table 8.3: Key Products Offered for Gastro-Intestinal Infection
  • Table 8.4: Key Products Offered for Center Nervous System Infection
  • Table 8.5: Key Products Offered for Hospital-Acquired Infections
  • Table 8.6: Key Products Offered for Sexually Transmitted Infections
  • Table 8.7: Key Products Offered for Other Applications

List of Figures

  • Figure 1: Number of COVID-19 Cases in Severely Affected Countries, as of April 8, 2020
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Infectious Disease Rapid Diagnostic Testing Market
  • Figure 3: Global Infectious Disease Rapid Diagnostic Testing Market (by Product), 2019 Vs. 2025, $Million
  • Figure 4: Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019 Vs. 2025, $Million
  • Figure 5: Global Infectious Disease Rapid Diagnostic Testing Market (by Disease Pathogen), 2019 Vs. 2025, $Million
  • Figure 6: Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019 Vs. 2025, $Million
  • Figure 7: Global Infectious Disease Rapid Diagnostic Testing Market (by End User), 2019 Vs. 2025, $Million
  • Figure 8: Global Infectious Disease Rapid Diagnostic Testing Market Snapshot
  • Figure 2.1: Global Infectious Disease Rapid Diagnostic Testing Market Segmentation
  • Figure 4.1: Comparison Between Commercially Available Infectious Disease RDT Products Vs. Laboratory Testing
  • Figure 4.2: Global Infectious Disease Rapid Diagnostic Market (by Infectious Disease), Pre-COVID-19 Vs. Post-COVID-19
  • Figure 4.3: Global Infectious Disease Rapid Diagnostic Testing Market, $Million, 2019-2025
  • Figure 4.4: Major Factors Considered
  • Figure 5.1: New Cases of Respiratory and Enteric Infections, Globally, 2012-2017
  • Figure 5.2: Time of Infectious Disease Pandemics
  • Figure 6.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Product), 2019-2025
  • Figure 6.2: Global Infectious Disease Rapid Diagnostic Market (by Assays), 2019-2025
  • Figure 6.3: Global Infectious Disease Rapid Diagnostic Market (Platforms), 2019-2025
  • Figure 7.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019-2025
  • Figure 7.2: Global Infectious Disease Rapid Diagnostic Market (RT-PCR), 2019-2025
  • Figure 7.3: Global Infectious Disease Rapid Diagnostic Market (by INAAT), 2019-2025
  • Figure 7.4: Global Infectious Disease Rapid Diagnostic Market (LFIA), 2019-2025
  • Figure 7.5: Global Infectious Disease Rapid Diagnostic Market (EIA), 2019-2025
  • Figure 7.6: Global Infectious Disease Rapid Diagnostic Market (Others), 2019-2025
  • Figure 8.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019-2025
  • Figure 8.2: Global Infectious Disease Rapid Diagnostic Market (Respiratory Infection), 2019-2025
  • Figure 8.3: Global Infectious Disease Rapid Diagnostic Market (Gastro-Intestinal Infection), 2019-2025
  • Figure 8.4: Global Infectious Disease Rapid Diagnostic Market (Center Nervous System Infection), 2019-2025
  • Figure 8.5: Global Infectious Disease Rapid Diagnostic Market (Hospital-Acquired Infection), 2019-2025
  • Figure 8.6: Global Infectious Disease Rapid Diagnostic Market (Sexually Transmitted Infections), 2019-2025
  • Figure 8.7: Global Infectious Disease Rapid Diagnostic Market (Other Applications), 2019-2025
  • Figure 9.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Disease), 2019 and 2025
  • Figure 9.2: Global Infectious Disease Rapid Diagnostic Market (by Bacterial Infection), 2019-2025
  • Figure 9.3: Global Infectious Disease Rapid Diagnostic Market for Hospital Acquired Infection, 2019-2025
  • Figure 9.4: Global Infectious Disease Rapid Diagnostic Market for Tuberculosis, 2019-2025
  • Figure 9.5: Global Infectious Disease Rapid Diagnostic Market for CT/NG, 2019-2025
  • Figure 9.6: Global Infectious Disease Rapid Diagnostic Market for Other Bacterial Infections, 2019-2025
  • Figure 9.7: Global Infectious Disease Rapid Diagnostic Market (by Viral Infection), 2019-2025
  • Figure 9.8: Global Infectious Disease Rapid Diagnostic Market Y-o-Y (by Viral Infection), 2019-2025
  • Figure 9.9: Global Infectious Disease Rapid Diagnostic Market for Influenza, 2019-2025
  • Figure 9.10: Global Infectious Disease Rapid Diagnostic Market for Hepatitis, 2019-2025
  • Figure 9.11: Global Infectious Disease Rapid Diagnostic Market for HIV-AIDS, 2019-2025
  • Figure 9.12: Global Infectious Disease Rapid Diagnostic Market for HPV, 2019-2025
  • Figure 9.13: Global Infectious Disease Rapid Diagnostic Market for Other Viral Infections, 2019-2025
  • Figure 9.14: Global Infectious Disease Rapid Diagnostic Market for Other Infections, 2019-2025
  • Figure 11.1: Global Infectious Disease Rapid Diagnostic Testing Market (by Region), 2020 and 2025
  • Figure 11.2: Global Infectious Disease Rapid Diagnostic Testing Market (by Region), 2019-2025
  • Figure 11.3: Number of Confirmed COVID-19 Cases in Severely Affected Countries, as of April 8, 2020
  • Figure 11.4: Global Infectious Disease Rapid Diagnostic Testing Market Share (by Region), 2019 and 2025
  • Figure 11.5: North America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.6: North America Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
  • Figure 11.7: North America: Market Dynamics
  • Figure 11.8: U.S. Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.9: Month-Wise COVID-19 Cases, the U.S., as of April 8, 2020
  • Figure 11.10: Canada Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.11: Month-Wise COVID-19 Cases, Canada, as of April 8, 2020
  • Figure 11.12: Europe Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.13: Europe: Market Dynamics
  • Figure 11.14: Europe Rapid Infectious Disease Diagnostic Testing Market (by Country), 2019-2025
  • Figure 11.15: Germany Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.16: Month-Wise COVID-19 Cases, Germany, as of April 8, 2020
  • Figure 11.17: U.K. Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.18: Month-Wise COVID-19 Cases, the U.K., as of April 8, 2020
  • Figure 11.19: France Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.20: Month-Wise COVID-19 Cases, France, as of April 8, 2020
  • Figure 11.21: Italy Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.22: Month-Wise COVID-19 Cases, Italy, as of April 8, 2020
  • Figure 11.23: Spain Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.24: Month-Wide COVID-19 Cases, Spain, as of April 8, 2020
  • Figure 11.25: Russia Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.26: Month-Wise COVID-19 Cases, Russia, as of April 8, 2020
  • Figure 11.27: Rest-of-Europe Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.28: APAC Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.29: APAC: Market Dynamics
  • Figure 11.30: APAC Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
  • Figure 11.31: China Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.32: Month-Wise COVID-19 Cases, China, as of April 8, 2020
  • Figure 11.33: Japan Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.34: Month-Wise COVID-19 Cases, Japan, as of April 8, 2020
  • Figure 11.35: India Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.36: Month-Wise COVID-19 Cases, India, as of April 8, 2020
  • Figure 11.37: Taiwan Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.38: Month-Wise COVID-19 Cases, Taiwan, as of April 8, 2020
  • Figure 11.39: South Korea Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.40: Month-Wise COVID-19 Cases, South Korea, as of April 8, 2020
  • Figure 11.41: Singapore Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.42: Month-Wise COVID-19 Cases, Singapore, as of April 8, 2020
  • Figure 11.43: Australia Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.44: Month-Wise COVID-19 Cases, Australia, as of April 8, 2020
  • Figure 11.45: Rest-of-APAC Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.46: Latin America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.47: Latin America: Market Dynamics
  • Figure 11.48: Latin America Infectious Disease Rapid Diagnostic Testing Market (by Country), 2019-2025
  • Figure 11.49: Brazil Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.50: Month-Wise COVID-19 Cases, Brazil, as of April 8, 2020
  • Figure 11.51: Mexico Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.52: Month-Wise COVID-19 Cases, Australia, as of April 8, 2020
  • Figure 11.53: Rest-of-Latin America Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.54: Middle East Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.55: Month-Wise COVID-19 Cases, KSA & UAE, as of April 8, 2020
  • Figure 11.56: Africa Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 11.57: Month-Wise COVID-19 Cases, Egypt, Ethiopia, Nigeria, and Democratic Republic of Congo, as of April 8, 2020
  • Figure 11.58: RoW Infectious Disease Rapid Diagnostic Testing Market, 2019-2025
  • Figure 12.1: Global Infectious Disease Rapid Diagnostic Market (by End User)
  • Figure 12.2: Global Infectious Disease Rapid Diagnostic Testing Market (by End User), 2019-2025
  • Figure 12.3: Global Infectious Disease Rapid Diagnostic Testing Market (by Hospitals), 2019-2025
  • Figure 12.4: Global Infectious Disease Rapid Diagnostic Testing Market (by Clinics), 2019-2025
  • Figure 12.5: Global Infectious Disease Rapid Diagnostic Testing Market (by Diagnostic Centers), 2019-2025
  • Figure 12.6: Global Infectious Disease Rapid Diagnostic Testing Market (by Other End Users), 2019-2025
  • Figure 13.1: Share of Key Developments and Strategies, 2016-2020
  • Figure 13.2: Product Approval Share (by Company), 2016 - 2020
  • Figure 13.3: Product Launch and Upgradation Share (by Company), 2016 -2020
  • Figure 13.4: Synergistic Activities Share (by Company), 2016 -2020
  • Figure 13.5: Funding and Expansion Share (by Company), 2016 -2020
  • Figure 13.6: Mergers and Acquisitions Share (by Company), 2016 -2020
  • Figure 13.7: Market Share Analysis for the Global Infectious Disease Rapid Diagnostic Testing Market, 2019
  • Figure 13.8: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Company), 2019
  • Figure 13.9: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Application), 2019
  • Figure 13.10: Growth Share Matrix for Global Infectious Disease Rapid Diagnostic Testing Market (by Technology), 2019
  • Figure 14.1: Total Number of Companies Profiled
  • Figure 14.2: Competitive Benchmarking of Abbott Laboratories
  • Figure 14.3: Competitive Benchmarking of F. Hoffmann-La Roche Ltd
  • Figure 14.4: Competitive Benchmarking of Danaher Corporation
  • Figure 14.5: Competitive Benchmarking of Luminex Corporation
  • Figure 14.6: Competitive Benchmarking of BGI Group
  • Figure 14.7: Competitive Benchmarking of bioMerieux S.A.
  • Figure 14.8: Competitive Benchmarking of DiaSorin S.p.A.
  • Figure 14.9: Competitive Benchmarking of Hologic, Inc.
  • Figure 14.10: Competitive Benchmarking of Mesa Biotech
  • Figure 14.11: Competitive Benchmarking of Quidel Corporation
  • Figure 14.12: Competitive Benchmarking of Thermo Fisher Scientific Inc.
  • Figure 14.13: Competitive Benchmarking of GenMark Diagnostics
  • Figure 14.14: Competitive Benchmarking of CTK Biotech
  • Figure 14.15: Competitive Benchmarking of Becton, Dickinson and Company
  • Figure 14.16: Competitive Benchmarking of Cellex
目次
Product Code: BH217A

“Global Infectious Disease Rapid Diagnostic Testing Market to Reach $2,853.2 Million by 2025.”

Market Segmentation

  • Product - Infectious Disease Diagnostics Assays and Platforms
  • Technology- Real-Time PCR , Isothermal Nucleic Acid Amplification Technology (INAAT), Lateral Flow Immunoassay, Enzyme Immunoassay, and Others
  • Disease- Bacterial, Viral, and Others
  • Application - Respiratory Infection, Gastro-intestinal Infection, Central Nervous System Infection, sexually transmitted infections, Hospital Acquired Infections and Other Infections
  • End User - Hospital, Clinics, Diagnostic Centers, and Other End Users

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Russia, and Rest-of-Europe
  • Asia-Pacific - China, Japan, India, Taiwan, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)
  • Latin America - Brazil, Mexico, and Rest-of-the-Latin America
  • Middle East
  • Africa
  • Rest-of-the-World

Growth Drivers

  • Rising Incidence of Frequent Pandemics such as COVID-19 Infectious Disease Inciting the Development of Rapid Diagnostic Assays
  • Significant Innovation Resulting in Market Pull
  • Shift from Centralized to Decentralized Laboratories
  • Significant External Funding for Executing R&D Exercises

Market Challenges

  • Lack of Standard Regulatory Processes
  • Shortage of Skilled Professionals and Trained Lab Technicians
  • Less Efficiency of Rapid Diagnostic Testing as Compared with Laboratory Testing

Market Opportunities

  • Development of Infectious Disease Diagnostic Assays for Various Clinical Areas
  • Massive Scope for Adoption of Infectious Disease Rapid Diagnostic Testing in Emerging Nations

Key Companies Profiled

Abbott Laboratories, F. Hoffman-La Roche Ltd, Danaher Corporation, Luminex Corporation, BGI Group, bioMerieux S.A., DiaSorin S.p.A, Hologic, Inc., Mesa Biotech, Quidel Corporation, Thermo Fisher Scientific Inc., GenMark Diagnostics, CTK Biotech, Becton, Dickinson and Company, and Cellex Inc.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global infectious disease rapid diagnostics testing market?
  • What are the underlying structures resulting in the emerging trends within the infectious disease diagnostic assays and systems?
  • What was the market value of the leading segments of the global infectious disease rapid diagnostics testing market in 2019?
  • What are the influencing factors that may affect the market share of the key players?
  • How is the industry expected to evolve during the forecast period 2020-2025?
  • What are the key developmental strategies which are implemented by the key players to sustain in the competitive market?
  • What is the current market share of each of the companies in the global infectious disease rapid diagnostics testing market and what are expected to be their contributions in 2025?
  • What is the growth potential of infectious disease diagnostics in each region, including North America, Europe, Asia-Pacific, Latin America, Middle East, Africa and Rest-of-the-World?
  • What are the key regulatory implications in developed and developing regions for infectious disease diagnostics?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2020-2025?
  • What key strategies have been incorporated by the leading players for furthering the growth of infectious disease industry?
  • How is a pandemic such as COVID-19 expected to impact development of rapid diagnostic for infectious disease testing?

Market Overview

Our healthcare experts have found infectious disease industry to be one of the most rapidly evolving markets. The global market for infectious disease rapid diagnostic testing is predicted to grow at a CAGR of 12.36% over the forecast period of 2020-2025. The market is driven by certain factors, which include the rising incidence of frequent pandemics such as COVID-19, infectious diseases inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.

The market is favored by the development of rapid diagnostics assays for several clinical areas such as respiratory infections, central nervous system infection, sexually transmitted infection, among others. Recent infectious disease outbreaks such as Zika, Ebola, and COVID- 19 have furthered the growth of the market.

Furthermore, several diagnostic companies are focusing on the development of rapid diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing diagnosis of an infectious disease at the point of care.

Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of rapid diagnostics providing accurate results at a shorter turn-around time. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.

Several other companies such as F. Hoffman-La Roche Ltd, GenMark Diagnostics Inc., and Bio-Rad Laboratories, among others, have launched diagnostics assays for COVID-19, such as cobas SARS-CoV-2 Test, ePlex SARS-CoV-2 Test, and Fast Track Diagnostics (FTD) SARS-CoV-2 Assay respectively, to compete with ABBOTT REALTIME SARS-COV-2 ASSAY market dominance.

On the basis of region, North America holds the largest share of infectious disease rapid diagnostic testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Definition by Products
    • 1.1.1 Platforms
    • 1.1.2 Assays
  • 1.2 Inclusion and Exclusion

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model

4 Market Overview

  • 4.1 Definitions
    • 4.1.1 Market Definition
    • 4.1.2 Definition by Products
      • 4.1.2.1 Platforms
      • 4.1.2.2 Assays
  • 4.2 Infectious Disease Rapid Diagnostic Technologies
  • 4.3 Situation Analysis: Pre-COVID Vs. Post-COVID
  • 4.4 Impact of COVID-19 on Infectious Disease Rapid Diagnostic Testing
    • 4.4.1 Impact of COVID-19 on Different Countries
  • 4.5 Market Size and Growth Potential, $Million, 2019-2025
    • 4.5.1 Overview
    • 4.5.2 Most Promising Countries in the Infectious Disease Rapid Diagnostic Testing Market
      • 4.5.2.1 U.S.
      • 4.5.2.2 Italy
      • 4.5.2.3 China
      • 4.5.2.4 India
      • 4.5.2.5 Brazil
      • 4.5.2.6 Kingdom of Saudi Arabia (K.S.A.)
      • 4.5.2.7 Democratic Republic of Congo

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Impact Analysis
  • 5.3 Drivers
    • 5.3.1 Rising Incidence of Frequent Pandemics, such as COVID-19 Infectious Disease, Inciting the Development of Rapid Diagnostic Assays
    • 5.3.2 Significant Innovation Resulting in Market Pull
    • 5.3.3 Shift from Centralized to Decentralized Laboratories
    • 5.3.4 Significant External Funding for Executing R&D Exercises
  • 5.4 Restraints
    • 5.4.1 Lack of Standard Regulatory Processes
    • 5.4.2 Shortage of Skilled Professionals and Trained Lab-Technicians
    • 5.4.3 Less Efficiency of Rapid Diagnostic Testing as Compared with that of Laboratory Testing
  • 5.5 Opportunities
    • 5.5.1 Development of Infectious Disease Diagnostic Assays for Various Clinical Areas

6 Global Infectious Disease Rapid Testing Market (by Product), $Million, 2019-2025

  • 6.1 Overview
  • 6.2 Assays
  • 6.3 Platforms

7 Global Infectious Disease Rapid Testing Market (by Technology), $Million, 2019-2025

  • 7.1 Overview
  • 7.2 Real-Time PCR (q-PCR)
  • 7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.4 Lateral Flow Immunoassay (LFIA)
  • 7.5 Enzyme Immunoassay (EIA)
  • 7.6 Others

8 Global Infectious Disease Rapid Testing Market (by Application), $Million, 2019-2025

  • 8.1 Overview
  • 8.2 Respiratory Infection
  • 8.3 Gastro-Intestinal Infection
  • 8.4 Center Nervous System Infection
  • 8.5 Hospital Acquired Infection
  • 8.6 Sexually Transmitted Infections
  • 8.7 Others

9 Global Infectious Disease Rapid Testing Market (by Disease), $Million, 2019-2025

  • 9.1 Overview
  • 9.2 Bacterial Infection
    • 9.2.1 Hospital Acquired Infections
    • 9.2.2 Tuberculosis
    • 9.2.3 CT/NG
    • 9.2.4 Others
  • 9.3 Viral Infections
    • 9.3.1 Influenza Virus
    • 9.3.2 Hepatitis
    • 9.3.3 HIV-AIDS
    • 9.3.4 HPV
    • 9.3.5 Others
  • 9.4 Other Infections

10 Emerging Companies in the Global Infectious Disease Rapid Diagnostic Testing Market

  • 10.1 XCR Diagnostics, Inc.
  • 10.2 Co-Diagnostics Inc.
  • 10.3 Inflammatix, Inc.
  • 10.4 DNA Electronics
  • 10.5 Mylab Discovery Solutions Pvt. Ltd.
  • 10.6 CerTest BIOTEC S.L.

11 Global Infectious Disease Rapid Diagnostic Testing Market (by Region)

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 Spain
    • 11.3.6 Russia
    • 11.3.7 Rest-of-Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Taiwan
    • 11.4.5 South Korea
    • 11.4.6 Singapore
    • 11.4.7 Australia
    • 11.4.8 Rest-of-APAC
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-Latin America
  • 11.6 Middle East
  • 11.7 Africa
  • 11.8 Rest-of-the-World (RoW)

12 Global Infectious Disease Rapid Diagnostic Testing Market (by End User)

  • 12.1 Overview
  • 12.2 Hospitals
  • 12.3 Clinics
  • 12.4 Diagnostic Centers
  • 12.5 Other End Users

13 Competitive Landscape

  • 13.1 Key Strategies and Developments
    • 13.1.1 Product Approvals
    • 13.1.2 Product Launches and Upgradations
    • 13.1.3 Synergistic Activities
    • 13.1.4 Funding and Expansion
    • 13.1.5 Mergers and Acquisitions
  • 13.2 Industry Trends
  • 13.3 Market Share Analysis (by Company), 2019
  • 13.4 Growth Share Analysis (Opportunity Mapping)
    • 13.4.1 By Company
    • 13.4.2 By Application
    • 13.4.3 By Technology

14 Company Profiles

  • 14.1 Overview
  • 14.2 Abbott Laboratories
    • 14.2.1 Company Overview
    • 14.2.2 BIS Insights
  • 14.3 F. Hoffmann-La Roche Ltd
    • 14.3.1 Company Overview
    • 14.3.2 BIS Insights
  • 14.4 Danaher Corporation
    • 14.4.1 Company Overview
    • 14.4.2 BIS Insights
  • 14.5 Luminex Corporation
    • 14.5.1 Company Overview
    • 14.5.2 BIS Insights
  • 14.6 BGI Group
    • 14.6.1 Company Overview
    • 14.6.2 BIS Insights
  • 14.7 bioMerieux S.A.
    • 14.7.1 Company Overview
    • 14.7.2 BIS Insights
  • 14.8 DiaSorin S.p.A
    • 14.8.1 Company Overview
    • 14.8.2 BIS Insights
  • 14.9 Hologic, Inc.
    • 14.9.1 Company Overview
    • 14.9.2 BIS Insights
  • 14.10 Mesa Biotech
    • 14.10.1 Company Overview
    • 14.10.2 BIS Insights
  • 14.11 Quidel Corporation
    • 14.11.1 Company Overview
    • 14.11.2 BIS Insights
  • 14.12 Thermo Fisher Scientific Inc.
    • 14.12.1 Company Overview
    • 14.12.2 BIS Insights
  • 14.13 GenMark Diagnostics
    • 14.13.1 Company Overview
    • 14.13.2 BIS Insights
  • 14.14 CTK Biotech
    • 14.14.1 Company Overview
    • 14.14.2 BIS Insights
  • 14.15 Becton, Dickinson and Company
    • 14.15.1 Company Overview
    • 14.15.2 BIS Insights
  • 14.16 Cellex
    • 14.16.1 Company Overview
    • 14.16.2 BIS Insights